Manufacturer
Takeda Austria GmbH
Contents
Brentuximab vedotin
Indication
Adult patients w/ relapsed or refractory CD30+ Hodgkin lymphoma (HL) following autologous stem cell transplant (ASCT) or at least 2 prior therapies when ASCT or multi-agent chemotherapy is not a treatment option & at increased risk of relapse or progression following ASCT; relapsed or refractory systemic anaplastic large cell lymphoma (sALCL); CD30+ cutaneous T-cell lymphoma (CTCL) after at least 1 prior systemic therapy.
Instruction
HL & sALCL 1.8 mg/kg IV infusion over 30 min every 3 wk. Patient who achieve stable disease Min: 8 cycles & up to max: 16 cycles. CTCL Up to 16 cycles. Hepatic & severe renal impairment 1.2 mg/kg IV infusion over 30 min every 3 wk.
Drug interaction
Increased MMAE exposure w/ strong CYP3A4 & P-gp inhibitor eg, ketoconazole. Reduced MMAE exposure w/ strong CYP3A4 inducer eg, rifampicin.
Malaysia
